Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  tetanus toxoid helper peptide
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-5 of 5 for your search:
Start Over
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000430929, UVACC-HIC-11491, UVACC-34104, UVACC-MEL-44, UVACC-GCRC-CLS013, UVACC-HITC-02620, MDA-2005-0070, Mel 44, NCT00118274
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 10134, UVACC-OVA-2, UVACC-PRC-236-02, OVA-2, UVACC-HIC-10134, NCT00373217
Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 11276, UVACC-OVA3, UVACC-33204, UVACC-HIC-11276, NCT00091273
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 12 and over
Sponsor: NCI, Other
Protocol IDs: 11490, UVACC-MEL-45, UVACC-34204, UVACC-HIC-11490, NCT00118313
Vaccine Therapy in Treating Patients With Advanced Melanoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 13498, R01CA057653, P30CA044579, UVACC-MEL-48, UVACC-IRB-13498, UVACC-PRC-450-07, Mel 48, NCT00705640
Start Over